Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 28 symbols : Pfe save search
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
potential license hiv
Epileptic Seizures Treatment Market is expected to Cross US$ 1.77 Billion by 2030 End, Says TMR
Published: 2021-09-28 (Crawled : 12:00) - prnewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
treatment
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -4.36%
H: 1.09%
C: -5.85%
covid fda children vaccine trial
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.73%
H: 0.13%
C: -0.44%
new drug fda drug hiv application granted grant
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Published: 2021-09-28 (Crawled : 06:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
disease phase 2 positive phase 2 results results vaccine response
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.